Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potassium dobesilate topical - DermAct Pharmaceutical

Drug Profile

Potassium dobesilate topical - DermAct Pharmaceutical

Alternative Names: 2,5-Dihydroxybenzenesulfonic-acid-monopotassium-salt; AM-001; Potassium-2,5-dihydroxybenzenesulfonate

Latest Information Update: 17 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DermAct Pharmaceutical
  • Developer AmDerma Pharmaceuticals; DermAct Pharmaceutical
  • Class Benzenesulfonates; Potassium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis
  • No development reported Actinic keratosis

Most Recent Events

  • 17 Sep 2020 No development reported - Phase-II for Actinic keratosis in USA (Topical)
  • 24 Apr 2018 AmDerma completes a phase II trial in Actinic keratosis in USA (Topical) (NCT03210740)
  • 12 Jun 2017 Phase-II clinical trials in Actinic keratosis in USA (Topical) (NCT03210740)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top